Dashboard
1
With a fall in Net Sales of -28.56%, the company declared Very Negative results in Mar 25
- OPERATING CASH FLOW(Y) Lowest at CNY 1,735.5 MM
- ROCE(HY) Lowest at 20.29%
- CASH AND EQV(HY) Lowest at CNY 6,401.74 MM
2
With ROE of 18.44%, it has a very expensive valuation with a 8.09 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 118,250 Million (Large Cap)
44.00
NA
1.52%
-0.28
18.44%
8.09
Revenue and Profits:
Net Sales:
2,228 Million
(Quarterly Results - Jun 2025)
Net Profit:
435 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.44%
0%
-17.44%
6 Months
-17.6%
0%
-17.6%
1 Year
-26.75%
0%
-26.75%
2 Years
-33.06%
0%
-33.06%
3 Years
-35.03%
0%
-35.03%
4 Years
-63.56%
0%
-63.56%
5 Years
-24.71%
0%
-24.71%
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.63%
EBIT Growth (5y)
12.96%
EBIT to Interest (avg)
84.28
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.69
Tax Ratio
15.18%
Dividend Payout Ratio
60.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
43.04%
ROE (avg)
21.78%
Valuation key factors
Factor
Value
P/E Ratio
44
Industry P/E
Price to Book Value
8.09
EV to EBIT
37.45
EV to EBITDA
36.08
EV to Capital Employed
10.82
EV to Sales
10.93
PEG Ratio
NA
Dividend Yield
1.52%
ROCE (Latest)
28.88%
ROE (Latest)
18.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,228.00
3,118.70
-28.56%
Operating Profit (PBDIT) excl Other Income
512.30
1,182.00
-56.66%
Interest
8.50
7.20
18.06%
Exceptional Items
-0.10
-7.60
98.68%
Consolidate Net Profit
434.50
1,013.50
-57.13%
Operating Profit Margin (Excl OI)
215.40%
368.70%
-15.33%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -28.56% vs 34.01% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -57.13% vs 264.83% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
10,718.50
9,977.90
7.42%
Operating Profit (PBDIT) excl Other Income
3,503.40
3,357.20
4.35%
Interest
40.10
39.80
0.75%
Exceptional Items
-8.90
8.30
-207.23%
Consolidate Net Profit
2,995.50
2,851.10
5.06%
Operating Profit Margin (Excl OI)
317.10%
323.60%
-0.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 7.42% vs 15.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.06% vs 13.00% in Dec 2023
About Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. 
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






